Search results
Results from the WOW.Com Content Network
This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Bumetanide oral liquid (S-95008) – sodium–potassium–chloride symporter/cotransporter inhibitor and indirect GABAergic inhibitor [3] [4] Cariprazine (Reagila, Symvenu, Vraylar; MP-214, RGH-188, WID-RGC20) – dopamine D 2 and D 3 receptor partial agonist, serotonin 5-HT 1A receptor partial agonist, serotonin 5-HT 2B receptor antagonist ...
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in June 2017.
Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD; Suboxone (buprenorphine/naloxone) - a partial opioid agonist used in the treatment of opioid use disorder
The complementary items either require additional infrastructure such as specially trained health care providers or diagnostic equipment or have a lower cost–benefit ratio. [4] The first list for children was created in 2007, and the list is in its 9th edition as of 2023. [4] [5] [6] [7]
List of investigational social anxiety disorder drugs This page was last edited on 28 October 2024, at 01:08 (UTC). Text is available under the Creative ...
The probe began in 2022 as child welfare advocates called for increased oversight of youth treatment centers following high-profile incidents of abuse and deaths at facilities around the country.
[34] [35] [36] There is one approved drug, sotorasib, that targets the KRAS G12C mutation, but only ~1% of PDACs have this mutation. [34] Another KRAS inhibitor, MRTX1133 targets G12D mutation which is present in over 40% of PDACs [37] [38] is currently in clinical trials to treat solid tumors including pancreatic adenocarcinoma. [39]